Breaking Finance News

A statement released earlier today by finnCap about Shield Therapeutics Plc (LON:STX) maintains the target price at 270.00GBX

Boasting a price of 157.50GBX, Shield Therapeutics Plc (LON:STX) traded 0.00% even on the day. With the last stock price close down -3.53% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Shield Therapeutics Plc has recorded a 50-day average of 157.50GBX and a two hundred day average of 163.26GBX. Volume of trade was up over the average, with 2,500 shares of STX changing hands over the typical 1,315

finnCap hold steady the target of Shield Therapeutics Plc (LON:STX) at 270.00GBX stating a potential upside of 0.71%.

On 09/07/2017, finnCap released a statement for Shield Therapeutics Plc (LON:STX) bumped up the target price from 0.00GBX to 270.00GBX that suggested an upside of 0%.

Performance Chart

Shield Therapeutics Plc (LON:STX)

With a total market value of 0 GBX, Shield Therapeutics Plc has with a 52 week low of 152.00GBX and a 52 week high of 177.00GBX .

Brief Synopsis On Shield Therapeutics Plc (LON:STX)

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.